News

Video

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Author(s):

Ulka Vaishampayan, MDAlan Tan, MD

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Related Videos
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Timothy Yap, MBBS, PhD, FRCP
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Timothy Yap, MBBS, PhD, FRCP
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Kohei Shitara, MD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Renal Cell Carcinoma - stock.adobe.com
May 27th 2024

Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 8th 2024

FDA Approval Insights: Ponatinib in Ph+ ALL

Renal Cell Carcinoma
May 21st 2024

TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC

FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
May 21st 2024

FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors